Adaptimmune Therapeutics PLC (ADAP)

[jondoeuk]

ASCO:

A Phase 2 Trial of ADP-A2M4 SPEAR T-Cells in Patients with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/description/ASCO20_Araujo_SPEARHEAD-1+TiP+e-poster+%28cm07%29_+FINAL_UPLOAD_13May20.pdf

Phase 1 Dose Escalation and Expansion Trial to Assess Safety and Efficacy of ADP-A2M4 in Advanced Solid Tumors https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/description/ASCO+DS+Hong_FINAL_13May2020+230PM.pdf

ASGCT:

Driving ADP-A2M4 SPEAR Expression from an Endogenous Hematopoietic Lineage Promotor for “Off-the-Shelf” T-Cell Therapy for MAGE-A4+ Solid Tumors https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/ASGCT+2020/Jill+Rogers+-+ASGCT+20_Hamilton+et+al_ADP-A2M4+poster+UPLOAD+FINAL+%28cm04+jwd+8May20%29.pdf

Differentiating T-Cells from hiPSCs to Create Off-the-Shelf SPEAR T-Cell Therapies https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/description/Brewer_Final_ASGCT+Presentation+May+2019.pdf

ILC:

Updated Data from Cohorts 1 and 2 of an Ongoing Study with ADP-A2AFP SPEAR T-Cells https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/ILC+2020/Jill+Rogers+-+Meyer+et+al_EASL+Poster+%28CM10+05Aug20%29_FINAL+ILC.pdf

Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T-cells https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/ILC+2020/Jill+Rogers+-+EASL-ILC_Oral+Presentation_B+Sangro_31July2020.pdf